---
title: "Johnson & Johnson (JNJ.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/JNJ.US.md"
symbol: "JNJ.US"
name: "Johnson & Johnson"
industry: "Pharmaceuticals"
---

# Johnson & Johnson (JNJ.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [www.jnj.com](https://www.jnj.com) |

## Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therap...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:13.000Z

**Overall: C (0.40)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 37 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 6.05% |  |
| Net Profit YoY | 90.56% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 7.30 |  |
| Dividend Ratio | 2.08% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 595.03B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 94.19B |  |


**Multi Score**: C

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 35.03% | A |
| Profit Margin | 28.46% | A |
| Gross Margin | 68.08% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 6.05% | C |
| Net Profit YoY | 90.56% | A |
| Total Assets YoY | 10.61% | B |
| Net Assets YoY | 14.06% | B |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 351.41% | C |
| OCF YoY | 6.05% | C |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.50 | C |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 59.07% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Johnson & Johnson",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "35.03%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "28.46%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "68.08%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "6.05%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "90.56%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "10.61%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "14.06%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "351.41%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "6.05%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.50",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "59.07%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Eli Lilly (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | Roche (US.RHHBY) | A | B | B | D | C | B |
| 04 | AstraZeneca (US.AZN) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 22.20 | 33/257 | 20.97 | 18.90 | 17.22 |
| PB | 7.30 | 164/257 | 6.25 | 5.48 | 4.82 |
| PS (TTM) | 6.32 | 103/257 | 5.38 | 4.68 | 4.19 |
| Dividend Yield | 2.08% | 20/257 | 3.20% | 2.87% | 2.48% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-19T05:00:00.000Z

Total Analysts: **26**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 9 | 35% |
| Overweight | 5 | 19% |
| Hold | 10 | 38% |
| Underweight | 1 | 4% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 242.49 |
| Highest Target | 265.00 |
| Lowest Target | 155.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/JNJ.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/JNJ.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/JNJ.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
